NRSN (NeuroSense Therapeutics) ROE % Adjusted to Book Value: 0.00% (As of Dec. 2025)


NRSN NeuroSense Therapeutics Ltd NRSN
29 GF Score
Price $0.76
! 2 Warning Signs
View Full Analysis

What is NeuroSense Therapeutics ROE % Adjusted to Book Value?

NeuroSense Therapeutics NRSN -0.13% 29 ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. GuruFocus rates NRSN with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

NeuroSense Therapeutics's ROE % for the quarter that ended in Dec. 2025 was 0.00%. NeuroSense Therapeutics's PB Ratio for the quarter that ended in Dec. 2025 was N/A. NeuroSense Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was N/A.

NeuroSense Therapeutics ROE % Adjusted to Book Value Related Terms

NeuroSense Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for NeuroSense Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroSense Therapeutics ROE % Adjusted to Book Value Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial -27.97 -56.05 0.00 -229.25 0.00

NeuroSense Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -166.05 0.00 0.00

NRSN vs SNTI, LSTA, DYAI: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, NeuroSense Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroSense Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where NeuroSense Therapeutics's ROE % Adjusted to Book Value falls into.


NRSN
29GF Score
NeuroSense Therapeutics Ltd NRSN
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroSense Therapeutics ROE % Adjusted to Book Value Calculation

NeuroSense Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-2,174.98% / N/A
=N/A

NeuroSense Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
NeuroSense Therapeutics (NRSN) has a ROE % Adjusted to Book Value of 0.00% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on NeuroSense Therapeutics and its competitors.
Is NeuroSense Therapeutics' ROE % Adjusted to Book Value too high?
NeuroSense Therapeutics' current ROE % Adjusted to Book Value is 0.00%. Overall, NeuroSense Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' ROE % Adjusted to Book Value compare to SNTI and LSTA?
NeuroSense Therapeutics' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on NeuroSense Therapeutics and its competitors. NeuroSense Therapeutics's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSN) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. NeuroSense Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSN), the current ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroSense Therapeutics Business Description

Other Exchanges H1Z:Germany
Address 11 HaMenofim Street, Building B, Herzliya, ISR, 4672562
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
29GF Score

Get the complete analysis for NRSN

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price